EUVIMEDEUVIMED entdecken
Open Access

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma

Neil S Horowitz, Richard T Penson, Dan G Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Kenneth S Cohen, Suzanne Berlin, Carolyn N Krasner, Marsha A Moses, Rakesh K Jain

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2011.04.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von Neil S Horowitz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Program, Brigham and Women's Hospital, Boston, MA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Gynecologic Oncology Program, Brigham and Women's Hospital, Boston, MA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Horowitz, N. S., Penson, R. T., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Cohen, K. S., Berlin, S., Krasner, C. N., Moses, M. A., & Jain, R. K. (2011). Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2011.04.003

Vancouver

Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, et al. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2011.04.003

BibTeX
@article{Horowitz2011,
  author = {Horowitz, Neil S and Penson, Richard T and Duda, Dan G and di Tomaso, Emmanuelle and Boucher, Yves and Ancukiewicz, Marek and Cohen, Kenneth S and Berlin, Suzanne and Krasner, Carolyn N and Moses, Marsha A and Jain, Rakesh K},
  title = {Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2011.04.003}
}
Kostenlos starten →